Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 501-507 , December 2009

New agents for AML and MDS

  • Steven Grant, MD (Professor)

      Affiliations

    • Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, VCU Health Systems, 401 College Street, Richmond, VA 23298-0035, USA
    • Department of Biochemistry, Virginia Commonwealth University and Massey Cancer Center, VCU Health Systems, 401 College Street, Richmond, VA 23298-0035,USA
    • Department of Pharmacology, Virginia Commonwealth University and Massey Cancer Center, VCU Health Systems, 401 College Street, Richmond, VA 23298-0035, USA
    • Corresponding Author InformationTel.: +1 804 828 5211; Fax: +1 804 828 2174.

References 

  1. Erba HP, Kantarjian H, Claxton DF, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood. 2008;112:209;(abstr 558)
  2. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112:1638–1645
  3. Lowenberg B, Burnett AK. Acute myeloid leukemia in adults. In:  Degos L,  Linch DC,  Lowenberg B editor. Textbook of malignant hematology. London: Taylor & Francis; 2005;p. 645
  4. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007;25:25–31
  5. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006;178–183
  6. Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005;23:31–37
  7. von Bubnoff N, Engh RA, Aberg E, et al. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a non-overlapping profile of resistance mutations in vitro. Cancer Res. 2009;69:3032–3041
  8. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2008;
  9. Shah NP, Kasap C, Weier C, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008;14:485–493
  10. Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007;67:6916–6924
  11. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–4169
  12. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110:4427–4435
  13. Hewamana S, Lin TT, Jenkins C, et al. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res. 2008;14:8102–8111
  14. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106:4261–4268
  15. Gu L, Gao J, Li Q, et al. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia. 2008;22:2091–2096
  16. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 2006;20:1254–1260
  17. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest. 2008;118:3003–3006
  18. Pawarode A, O'Loughlin KL, Cuviello NW, et al. The mTOR inhibitor rapamycin inhibits drug transport in multidrug resistant cell lines and in acute myeloid leukemia (ANL) cells. Blood. 2005;106:435a;(abstr1512)
  19. Neubauer A, Maharry K, Mrozek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26:4603–4609
  20. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008;14:3077–3082
  21. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387–1394
  22. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16:1111–1120
  23. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060–1066
  24. Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112:981–989
  25. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–692
  26. Muller-Thomas C, Schuster T, Peschel C, et al. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009;88:213–219
  27. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232
  28. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271–3279
  29. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A study of the New York Cancer Consortium. Blood. 2008;112:1252;(abstr 3656)
  30. Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008;15(Suppl.):40–49
  31. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361–6369
  32. Gao S, Mobley A, Miller C, et al. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res. 2008;32:771–780
  33. Issa J-P, Castoro R, Ravandi-Kashani F, et al. Randomized phase II study of combined epigenetic therapy: decitabine vs decitabine and valproic acid in MDS and AML. Blood. 2008;112:91;(abstr 228)
  34. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–2308
  35. Gorczynski MJ, Grembecka J, Zhou Y, et al. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol. 2007;14:1186–1197
  36. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727–738
  37. National Cancer Institute . Bortezomib and vorinostat in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Available from: http://clinicaltrials.gov/ct2/show/NCT00839956[accessed 17.04.09]
  38. National Cancer Institute . Bortezomib and vorinostat in treating patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00818649[accessed 17.04.09]

PII: S1521-6926(09)00061-9

doi: 10.1016/j.beha.2009.08.003

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 501-507 , December 2009

Article Tools